[1]
Yousef, M.H.; Al, J.A.; Albarrak, A.A.; Ibdah, J.A.; Tahan, V. Fatty liver without a large “belly”: Magnified review of non-alcoholic fatty liver disease in non-obese patients. World J. Gastrointest. Pathophysiol., 2017, 8(3), 100-107.
[2]
Namekawa, J.; Takagi, Y.; Wakabayashi, K.; Nakamura, Y.; Watanabe, A.; Nagakubo, D.; Shirai, M.; Asai, F. Effects of high-fat diet and fructose-rich diet on obesity, dyslipidemia and hyperglycemia in the WBN/Kob-Leprfa rat, a new model of type 2 diabetes mellitus. J. Vet. Med. Sci., 2017, 79(6), 988-991.
[3]
Johnson, R.J.; Nakagawa, T.; Sanchez-Lozada, L.G.; Shafiu, M.; Sundaram, S.; Le, M.; Ishimoto, T.; Sautin, Y.Y.; Lanaspa, M.A. Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes, 2013, 62(10), 3307-3315.
[4]
Jegatheesan, P.; De Bandt, J.P. Fructose and NAFLD: the multifaceted aspects of fructose metabolism. Nutrients, 2017, 9(3), 230.
[5]
Baena, M.; Sanguesa, G.; Hutter, N.; Sanchez, R.M.; Roglans, N.; Laguna, J.C.; Alegret, M. Fructose supplementation impairs rat liver autophagy through mTORC activation without inducing endoplasmic reticulum stress. Biochim. Biophys. Acta, 2015, 1851(2), 107-116.
[6]
Debosch, B.J.; Chen, Z.; Saben, J.L.; Finck, B.N.; Moley, K.H. Glucose transporter 8 (GLUT8) mediates fructose-induced de novo lipogenesis and macrosteatosis. J. Biol. Chem., 2014, 289(16), 10989-10998.
[7]
Ezquerro, S.; Mendez-Gimenez, L.; Becerril, S.; Moncada, R.; Valenti, V.; Catalan, V.; Gomez-Ambrosi, J.; Fruhbeck, G.; Rodriguez, A. Acylated and desacyl ghrelin are associated with hepatic lipogenesis, beta-oxidation and autophagy: Role in NAFLD amelioration after sleeve gastrectomy in obese rats. Sci. Rep., 2016, 6(39942)
[8]
Rotman, Y.; Sanyal, A.J. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut, 2017, 66(1), 180-190.
[9]
Abenavoli, L.; Bellentani, S. Milk thistle to treat non-alcoholic fatty liver disease: dream or reality? Expert Rev. Gastroenterol. Hepatol., 2013, 7(8), 677-679.
[10]
Gabrielova, E.; Zholobenko, A.V.; Bartosikova, L.; Necas, J.; Modriansky, M. Silymarin constituent 2,3-dehydrosilybin triggers reserpine-sensitive positive inotropic effect in perfused rat heart. PLoS One, 2015, 10(9)e139208
[11]
Gu, M.; Zhao, P.; Huang, J.; Zhao, Y.; Wang, Y.; Li, Y.; Li, Y.; Fan, S.; Ma, Y.M.; Tong, Q.; Yang, L.; Ji, G.; Huang, C. Silymarin ameliorates metabolic dysfunction associated with diet-induced obesity via activation of farnesyl x receptor. Front. Pharmacol., 2016, 7(345)
[12]
Stiuso, P.; Scognamiglio, I.; Murolo, M.; Ferranti, P.; De Simone, C.; Rizzo, M.R.; Tuccillo, C.; Caraglia, M.; Loguercio, C.; Federico, A. Serum oxidative stress markers and lipidomic profile to detect NASH patients responsive to an antioxidant treatment: A pilot study. Oxid. Med. Cell. Longev., 2014, 2014(2)169216
[13]
Polimeni, L.; Del, B.M.; Baratta, F.; Perri, L.; Albanese, F.; Pastori, D.; Violi, F.; Angelico, F. Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis. World J. Hepatol., 2015, 7(10), 1325-1336.
[14]
Song, X.; Liu, B.; Cui, L.; Zhou, B.; Liu, W.; Xu, F.; Hayashi, T.; Hattori, S.; Ushiki-Kaku, Y.; Tashiro, S.I.; Ikejima, T. Silibinin ameliorates anxiety/depression-like behaviors in amyloid beta-treated rats by upregulating BDNF/TrkB pathway and attenuating autophagy in hippocampus. Physiol. Behav., 2017, 179, 487-493.
[15]
Zheng, N.; Liu, L.; Liu, W.W.; Li, F.; Hayashi, T.; Tashiro, S.I.; Onodera, S.; Ikejima, T. Crosstalk of ROS/RNS and autophagy in silibinin-induced apoptosis of MCF-7 human breast cancer cells in vitro. Acta Pharmacol. Sin., 2017, 38(2), 277-289.
[16]
Wang, M.; Li, Y.J.; Ding, Y.; Zhang, H.N.; Sun, T.; Zhang, K.; Yang, L.; Guo, Y.Y.; Liu, S.B.; Zhao, M.G.; Wu, Y.M. Silibinin prevents autophagic cell death upon oxidative stress in cortical neurons and cerebral ischemia-reperfusion injury. Mol. Neurobiol., 2016, 53(2), 932-943.
[17]
Ghareghani, P.; Shanaki, M.; Ahmadi, S.; Khoshdel, A.R.; Rezvan, N.; Meshkani, R.; Delfan, M.; Gorgani-Firuzjaee, S. Aerobic endurance training improves nonalcoholic fatty liver disease (NAFLD) features via miR-33 dependent autophagy induction in high fat diet fed mice. Obes. Res. Clin. Pract., 2017, 12(2), 80-89.
[18]
Singh, R.; Kaushik, S.; Wang, Y.; Xiang, Y.; Novak, I.; Komatsu, M.; Tanaka, K.; Cuervo, A.M.; Czaja, M.J. Autophagy regulates lipid metabolism. Nature, 2009, 458(7242), 1131-1135.
[19]
Shibata, M.; Yoshimura, K.; Furuya, N.; Koike, M.; Ueno, T.; Komatsu, M.; Arai, H.; Tanaka, K.; Kominami, E.; Uchiyama, Y. The MAP1-LC3 conjugation system is involved in lipid droplet formation. Biochem. Biophys. Res. Commun., 2009, 382(2), 419-423.
[20]
Park, H.W.; Lee, J.H. Calcium channel blockers as potential therapeutics for obesity-associated autophagy defects and fatty liver pathologies. Autophagy, 2014, 10(12), 2385-2386.
[21]
Nascimbeni, F.; Pais, R.; Bellentani, S.; Day, C.P.; Ratziu, V.; Loria, P.; Lonardo, A. From NAFLD in clinical practice to answers from guidelines. J. Hepatol., 2013, 59(4), 859-871.
[22]
Ren, L.P.; Yu, X.; Song, G.Y.; Zhang, P.; Sun, L.N.; Chen, S.C.; Hu, Z.J.; Zhang, X.M. Impact of activating transcription factor 4 signaling on lipogenesis in HepG2 cells. Mol. Med. Rep., 2016, 14(2), 1649-1658.
[23]
Zhang, Y.; Hai, J.; Cao, M.; Zhang, Y.; Pei, S.; Wang, J.; Zhang, Q. Silibinin ameliorates steatosis and insulin resistance during non-alcoholic fatty liver disease development partly through targeting IRS-1/PI3K/Akt pathway. Int. Immunopharmacol., 2013, 17(3), 714-720.
[24]
Gu, M.; Zhao, P.; Huang, J.; Zhao, Y.; Wang, Y.; Li, Y.; Li, Y.; Fan, S.; Ma, Y.M.; Tong, Q.; Yang, L.; Ji, G.; Huang, C. Silymarin ameliorates metabolic dysfunction associated with diet-induced obesity via activation of farnesyl x receptor. Front. Pharmacol., 2016, 7(345)
[25]
Anding, A.L.; Baehrecke, E.H. Autophagy in cell life and cell death. Curr. Top. Dev. Biol., 2015, 114, 67-91.
[26]
Sinha, R.A.; You, S.H.; Zhou, J.; Siddique, M.M.; Bay, B.H.; Zhu, X.; Privalsky, M.L.; Cheng, S.Y.; Stevens, R.D.; Summers, S.A.; Newgard, C.B.; Lazar, M.A.; Yen, P.M. Thyroid hormone stimulates hepatic lipid catabolism via activation of autophagy. J. Clin. Invest., 2012, 122(7), 2428-2438.
[27]
Sinha, R.A.; Farah, B.L.; Singh, B.K.; Siddique, M.M.; Li, Y.; Wu, Y.; Ilkayeva, O.R.; Gooding, J.; Ching, J.; Zhou, J.; Martinez, L.; Xie, S.; Bay, B.H.; Summers, S.A.; Newgard, C.B.; Yen, P.M. Caffeine stimulates hepatic lipid metabolism by the autophagy-lysosomal pathway in mice. Hepatology, 2014, 59(4), 1366-1380.
[28]
Ma, D.; Molusky, M.M.; Song, J.; Hu, C.R.; Fang, F.; Rui, C.; Mathew, A.V.; Pennathur, S.; Liu, F.; Cheng, J.X.; Guan, J.L.; Lin, J.D. Autophagy deficiency by hepatic FIP200 deletion uncouples steatosis from liver injury in NAFLD. Mol. Endocrinol., 2013, 27(10), 1643-1654.
[29]
Seo, Y.K.; Jeon, T.I.; Chong, H.K.; Biesinger, J.; Xie, X.; Osborne, T.F. Genome-wide localization of SREBP-2 in hepatic chromatin predicts a role in autophagy. Cell Metab., 2011, 13(4), 367-375.
[30]
Nalbandian, A.; Llewellyn, K.J.; Nguyen, C.; Yazdi, P.G.; Kimonis, V.E. Rapamycin and chloroquine: The in vitro and in vivo effects of autophagy-modifying drugs show promising results in valosin containing protein multisystem proteinopathy. PLoS One, 2015, (10)4 e122888
[31]
Tanaka, S.; Hikita, H.; Tatsumi, T.; Sakamori, R.; Nozaki, Y.; Sakane, S.; Shiode, Y.; Nakabori, T.; Saito, Y.; Hiramatsu, N.; Tabata, K.; Kawabata, T.; Hamasaki, M.; Eguchi, H.; Nagano, H.; Yoshimori, T.; Takehara, T. Rubicon inhibits autophagy and accelerates hepatocyte apoptosis and lipid accumulation in nonalcoholic fatty liver disease in mice. Hepatology, 2016, 64(6), 1994-2014.
[32]
Figarola, J.L.; Singhal, J.; Tompkins, J.D.; Rogers, G.W.; Warden, C.; Horne, D.; Riggs, A.D.; Awasthi, S.; Singhal, S.S. SR4 uncouples mitochondrial oxidative phosphorylation, modulates amp-dependent Kinase (AMPK)-mammalian target of rapamycin (mTOR) signaling, and inhibits proliferation of hepg2 hepatocarcinoma cells. J. Biol. Chem., 2015, 290(51), 30321-30341.
[33]
Smith, B.K.; Marcinko, K.; Desjardins, E.M.; Lally, J.S.; Ford, R.J.; Steinberg, G.R. Treatment of nonalcoholic fatty liver disease: Role of AMPK. Am. J. Physiol. Endocrinol. Metab., 2016, 311(4), E730-E740.
[34]
Figarola, J.L.; Singhal, J.; Tompkins, J.D.; Rogers, G.W.; Warden, C.; Horne, D.; Riggs, A.D.; Awasthi, S.; Singhal, S.S. SR4 uncouples mitochondrial oxidative phosphorylation, modulates AMP-dependent kinase (AMPK)-mammalian target of rapamycin (mTOR) signaling, and inhibits proliferation of HepG2 hepatocarcinoma cells. J. Biol. Chem., 2015, 51, 30321-30341.
[35]
Kim, Y.C.; Guan, K.L. mTOR: A pharmacologic target for autophagy regulation. J. Clin. Invest., 2015, 125(1), 25-32.
88
7